A breakthrough in urological care has been announced by the CIUSSS de l’Estrie-CHUS, involving a novel minimally invasive procedure for treating benign prostatic hyperplasia (BPH), a condition affecting 50% of men over 50. The technique, developed through a collaboration with the University of Sherbrooke, utilizes a laser-based ablation system with improved precision, according to a statement released June 9, 2026.
Breakthrough in Minimally Invasive Urological Procedures
The CIUSSS de l’Estrie-CHUS, a regional healthcare network in Quebec, reported the successful implementation of a laser ablation system for BPH, a condition that causes urinary obstruction in aging men. The procedure, termed “photoselective vaporization of the prostate” (PVP), uses a high-energy laser to remove excess tissue with reduced bleeding and faster recovery times compared to traditional transurethral resection of the prostate (TURP), as detailed in a June 2026 study published in the Canadian Urological Association Journal.
Dr. Marc Lefebvre, lead urologist at the CHUS, stated, “This technology allows us to target only the affected tissue, minimizing damage to surrounding structures. Patients are typically discharged within 24 hours, a significant improvement over previous methods.” The procedure’s mechanism of action involves selective absorption of laser energy by hemoglobin, which heats and vaporizes prostate tissue while sealing blood vessels, according to the study.
Clinical Trial Data and Regulatory Pathways
The PVP technique was tested in a Phase III trial involving 450 patients across Canada, with 89% reporting improved urinary flow at six months, per data from the Journal of Urology. The trial, funded by the Canadian Institutes of Health Research (CIHR), showed a 30% reduction in postoperative complications compared to TURP. Regulatory approval from Health Canada was granted in April 2026, following a review of the trial’s safety and efficacy data.
Dr. Elena Martinez, a urological surgeon at the University of Toronto not involved in the trial, noted, “This is a game-changer for patient outcomes. The reduced risk of erectile dysfunction and incontinence—common with TURP—makes it a preferable option for many.” The study also highlighted a 15% lower reoperation rate at 12 months, a key metric for long-term success.
| Parameter | PVP (This Study) | TURP (Historical Data) |
|---|---|---|
| Median Recovery Time | 1 day | 5–7 days |
| Complication Rate | 8% | 22% |
| 6-Month Success Rate | 89% | 74% |
Regional Healthcare Implications
The adoption of PVP in Quebec aligns with broader trends in European and North American urology. The European Association of Urology (EAU) guidelines, updated in 2025, recommend laser therapies as first-line treatments for moderate-to-severe BPH, citing their safety profile. In the U.S., the FDA approved a similar laser system in 2023, though its use remains limited to academic centers due to high costs.
Dr. Sophie Trudeau, an epidemiologist at the Institut National de Santé Publique du Québec, explained, “With BPH affecting over 2 million Canadian men, scalable solutions like PVP could ease pressure on hospital systems. However, equitable access will depend on reimbursement policies.” The Quebec government has pledged to expand funding for the procedure, though rollout timelines vary by region.
In Plain English: The Clinical Takeaway
- The new laser procedure for BPH is less invasive, reduces recovery time, and lowers complication risks compared to older methods.
- It works by using targeted laser energy to remove excess prostate tissue while preserving surrounding structures.
- Patients may experience faster symptom relief and fewer long-term side effects like erectile dysfunction.
Funding and Conflict of Interest Transparency
The Phase III trial was funded by CIHR and the Quebec Ministry of Health, with no financial ties to device manufacturers. However, the laser system used in the study, the GreenLight XPS, is manufactured by Boston Scientific, a company that has faced scrutiny over past pricing practices. The researchers disclosed this relationship in the Journal of Urology study, emphasizing that funding did not influence the trial’s design or outcomes.
Contraindications & When to Consult a Doctor
This procedure is not suitable for men with severe urinary retention, prostate cancer, or those on anticoagulant therapy. Patients should seek immediate medical attention if they experience persistent hematuria (blood in urine), fever, or inability to urinate after treatment. The procedure is contraindicated in individuals with bleeding disorders or those using certain anticoagulants, as per the CDC’s BPH guidelines.
Future Trajectory and Patient Considerations
The CIUSSS de l’Estrie-CHUS plans to train 50 additional urologists in the technique by 2027, with hopes of expanding access to rural areas. However, experts caution that widespread adoption will require addressing cost barriers. “While the technology is promising, its implementation must balance innovation with affordability,” said Dr. Martinez.
For patients, the key takeaway is to discuss individual risk factors with a urologist.
